AcelRx Pharmaceuticals Announces Sublingual Sufentanil Data Presentation at the American Society of Regional Anesthesia and Pain Medicine Meeting

AcelRx Pharmaceuticals, Inc.

, a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, announced today that a moderated poster presentation will be made at the Emerging Technology session of the American Society of Regional Anesthesia and Pain Medicine (ASRA) 14th Annual Pain Medicine Meeting to be held November 19th to November 21st at the Fontainebleau Miami Beach in Miami, Florida. The annual ASRA meeting is the foremost scientific and educational event on invasive and non-invasive targeted therapies in pain medicine and brings together nearly 1,000 national and international thought leaders. Pamela Palmer, M.D. Ph.D., AcelRx Co-founder and Chief Medical Officer, will present safety and efficacy data from a Phase 3 trial, SAP301, evaluating the sufentanil sublingual 30 mcg tablet, or ARX-04, for the treatment of acute pain following ambulatory surgery. Details on the presentation times are as follows: Thursday, November 19, 2015 – Emerging Technology Moderated Poster Session, MP-02, Presentation time 10:45-12:45pm (local time), Splash 13 Authors: Harold Minkowitz, MD, Shankar Lakshman, MD, Timothy Melson, MD, David Leiman, MD, Karen DiDonato, MSN, RN and Pamela Palmer, MD, PhD Title: Safety and Efficacy Subgroup Analysis by Age of Sufentanil Sublingual 30 mcg Tablets for the Treatment of Acute Pain following Outpatient Abdominal Surgery